Literature DB >> 28489478

Continuous Intravenous Lidocaine Infusion for the Management of Pain Uncontrolled by Opioid Medications.

David J Reeves, Alexandra E Foster.   

Abstract

Limited data exist describing the outcomes of patients receiving continuous lidocaine infusions. The objective of this study was to evaluate the effect of use of continuous lidocaine infusions for pain management at a community teaching hospital. A retrospective chart review was performed that included adult patients receiving continuous systemic lidocaine infusions for the treatment of pain. Twenty-one patients were included in the analysis. Dosing ranged from 0.25 to 2.8 mg/kg/h, with a median infusion time of 64 hours. Eight patients (38%) experienced a response (≥20% reduction in pain score during the infusion compared with prior to the infusion). Among responding patients, there was a decrease in pain scores at rest after starting lidocaine (compared with prior to lidocaine) (6.5 vs. 3.7, P = .001) that was maintained 24 hours after lidocaine discontinuation. There were no differences in pain scores before, during, or after lidocaine in the entire study sample. A difference in oral morphine equivalent intake was present comparing usage during the infusion vs. day +1 (P = .006) and day +2 (P < .001). Similarly, a difference was present comparing morphine equivalent usage on day -2 with day +2 (P = .008) and day -1 with day +1 (P = .006). Continuous infusions of systemic lidocaine appear to be beneficial in some patients experiencing uncontrolled pain and may improve pain scores while decreasing opioid requirements. Overall beneficial effects of systemic lidocaine may last longer than the infusion itself.

Entities:  

Keywords:  infusion; lidocaine; opioid; pain; uncontrolled

Mesh:

Substances:

Year:  2017        PMID: 28489478     DOI: 10.1080/15360288.2017.1313356

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  6 in total

1.  Intravenous infusion of lidocaine enhances the efficacy of conventional treatment of postherpetic neuralgia.

Authors:  Xinran Tan; Lulin Ma; Jie Yuan; Dexin Zhang; Jie Wang; Wenjing Zhou; Song Cao
Journal:  J Pain Res       Date:  2019-08-20       Impact factor: 3.133

2.  Effect of Intravenous Lidocaine on Postoperative Pain in Patients Undergoing Intraspinal Tumor Resection: Study Protocol for a Prospective Randomized Controlled Trial.

Authors:  Hongli Yue; Man Zhou; Yu Lu; Liang Chen; Weihua Cui
Journal:  J Pain Res       Date:  2020-06-12       Impact factor: 3.133

3.  Intravenous lidocaine alleviates postherpetic neuralgia in rats via regulation of neuroinflammation of microglia and astrocytes.

Authors:  Lulin Ma; Juan Li; Junli Zhou; Dexin Zhang; Zhi Xiao; Tian Yu; Ying Li; Song Cao
Journal:  iScience       Date:  2021-01-26

4.  Lidocaine attenuates CFA-induced inflammatory pain in rats by regulating the MAPK/ERK/NF-κB signaling pathway.

Authors:  Shuli Zhang; Yan Li; Yingjun Tu
Journal:  Exp Ther Med       Date:  2021-01-14       Impact factor: 2.447

5.  Effects of Lidocaine on Motor-Evoked Potentials and Somatosensory-Evoked Potentials in Patients Undergoing Intraspinal Tumour Resection: Study Protocol for a Prospective Randomized Controlled Trial.

Authors:  Hongli Yue; Man Zhou; Yingzi Chong; Miao Cheng; Hui Qiao; Yu Lu; Weihua Cui
Journal:  J Pain Res       Date:  2022-02-02       Impact factor: 3.133

6.  Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial.

Authors:  Yan Xu; Mao Ye; Ying Hong; Yi Kang; Yue Li; Xiao Xiao; Li Zhou; Chunling Jiang
Journal:  J Pain Res       Date:  2021-12-01       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.